Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) still in Phase 3 trials, marketed as more effective than Tirzepatides dual mechanism
But some people might be more susceptible to the effects on smooth muscle function. Erectile dysfunction could be the sign of other health issues unrelated to GLP-1 medications
DiMarchi had just left Lilly after working there for 22 years where he and Tschp had first met

Key Takeaways Cagrilintide is a long-acting amylin analogue with clinical trial doses ranging from 0.3 mg to 4.5 mg weekly, while retatrutide is a triple agonist studied at 4 mg, 8 mg, and 12 mg weekly doses No published clinical trials currently exist evaluating the cagrilintide dosage with retatrutide combination, making any combined use experimental and off-label Both peptides work through different mechanismscagrilintide activates amylin receptors while retatrutide targets GIP, GLP-1, and glucagon receptorssuggesting potential complementary effects Gastrointestinal side effects (nausea, vomiting) occur in 60-80% of participants at higher doses for both compounds, raising concerns about additive effects when combined Proper dose escalation protocols spanning 8-20 weeks are critical for tolerability and adherence in peptide-based metabolic therapies Understanding Cagrilintide: Mechanism and Dosage Fundamentals What Is Cagrilintide

Consider adding electrolytes to your water, especially in the first few weeks
Gregory EH, Pfaff DW (1971) Development of olfactory-guided behavior in infant rats